Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease
Researchers describe the discovery of potent, selective small-molecule APOL1 inhibitors and show that blocking APOL1 channel activity stops APOL1-mediated cell death and kidney damage, supporting a precision-medicine approach to APOL1-mediated kidney disease.
Background
Genome-wide association studies identified the G1 and G2 variants in the apolipoprotein L1 (APOL1) gene as major contributors to a subtype of proteinuric kidney disease now termed APOL1-mediated kidney disease (AMKD), which disproportionately affects people of recent African ancestry. Despite this known genetic cause, there are no disease-modifying therapies that address the underlying mechanism. The authors hypothesized that inhibiting APOL1 could be therapeutic for this genetically defined disease.
Key recommendations
The work describes development of preclinical assays and the discovery of potent and specific APOL1 inhibitors with drug-like properties. It provides evidence that APOL1 channel activity drives podocyte injury and that inhibition of this activity stops APOL1-mediated cell death and kidney damage in a transgenic mouse model. These preclinical findings are combined with previously published phase 2 proof-of-concept clinical data.
Clinical implications
Together, the preclinical and clinical evidence supports APOL1 channel inhibition as a precision-medicine strategy for AMKD, targeting the underlying genetic driver rather than only downstream proteinuria. This approach would make APOL1 genotyping increasingly relevant for identifying patients who could benefit from targeted therapy.
Category
News
Source
Nature Communications
More from ASNRT News
Browse the latest news, society announcements, KDIGO guideline updates, and AJNT issue releases on the ASNRT newsroom.